Biweekly Carboplatin/Gemcitabine in Patients with Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: Report of Efficacy, Quality of Life and Geriatric Assessment
2007; Karger Publishers; Volume: 73; Issue: 5-6 Linguagem: Inglês
10.1159/000132394
ISSN1423-0232
AutoresAristotle Bamias, G. Lainakis, Efstathios Kastritis, Nikos Antoniou, G. Alivizatos, Ανδρέας Κουρέας, Michael Chrisofos, Andreas Skolarikos, Evangelos Karayiotis, Meletios Α. Dimopoulos,
Tópico(s)Occupational and environmental lung diseases
ResumoWe evaluated safety and efficacy of first-line gemcitabine/carboplatin in unfit-for-cisplatin patients with advanced urothelial carcinoma and the effect on the quality of life and functional status of elderly patients (aged >70).Unfit patients had ECOG performance status (PS) > or =2, creatinine clearance or =2 comorbidities).Thirty-four patients were enrolled: 68% had PS 2-3, 69% a creatinine clearance <50 ml/min and 65% had 1 or more comorbidities. There were 3 cases of grade 3 toxicity (9%). Response rate was 24% [95% confidence interval (CI) 11-41]. Median follow-up was 8 months, median progression-free survival 4.4 months (95% CI 1.03-7.75) and median overall survival 9.8 months (95% CI 4.7-14.9). Patients in geriatric assessment groups 1 and 2 had a significantly longer median progression-free survival compared to group 3 [6.9 months (95% CI 1.3-12.4) vs. 1.9 months (95% CI 0.5-3.2); p = 0.005].First-line gemcitabine/carboplatin combination is active in unfit-for-cisplatin patients with advanced urothelial carcinoma. Pretreatment quality of life and geriatric assessment may be useful in selecting patients likely to benefit from this treatment.
Referência(s)